Alamar Biosciences, Inc.

Alamar Biosciences, Inc. is a biotechnology company headquartered in Fremont, California, dedicated to advancing precision proteomics for the earliest detection of disease. The company's mission is to power protein analysis with ultra-high sensitivity and specificity, enabling researchers to gain deeper insights into biological processes and disease states.

The company's core offerings revolve around its proprietary NULISA™ technology and the ARGO™ HT System, which together form a precision proteomics platform. This platform facilitates the detection and quantification of protein biomarkers with attomolar sensitivity and a broad dynamic range, even from minimal biofluid volumes. Key products include NULISAseq™ Panels for neurology, immunology, and oncology research, such as the NULISAseq Neuro 220 Panel, as well as NULISAqpcr™ Assays and a Dried Blood Spot Extraction Kit. These solutions support biomarker discovery, validation, and early disease detection across various therapeutic areas, including neurodegenerative diseases like Alzheimer's, inflammation, and cancer.

Alamar Biosciences completed its initial public offering (IPO) on April 17, 2026, and is now traded on NASDAQ under the ticker ALMR. Recent developments include the launch of the NULISAseq™ Neuro 220 Panel in March 2026 and the introduction of the first commercial blood-based eMTBR-Tau immunoassay for Alzheimer's disease in July 2026, which will be prominently featured at the Alzheimer's Association International Conference (AAIC) 2026. The leadership team includes Founder, Chairman, and CEO Dr. Yuling Luo, President Tod White, and CFO Justin McAnear. The company continues to expand its offerings, including a home fingerstick kit for remote sample collection, solidifying its position as a leader in precision proteomics.